Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT™, and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. Nemaura is planning to submit a PMA application for sugarBEAT® during the second quarter of 2020 for FDA review of this device under medical device regulations. proBEAT™ comprises a non-invasive glucose monitor and a digital healthcare subscription service and is due to be launched in the US as a general wellness product.
Company profile
Ticker
NMRD
Exchange
Website
CEO
Dewan Chowdhury
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Dermal Diagnostics (Holdings) Limited • Dermal Diagnostics Limited • Trial Clinic Limited ...
NMRD stock data
Analyst ratings and price targets
Latest filings (excl ownership)
S-1
IPO registration
13 Mar 23
8-K
Nemaura Medical Announces Receipt of Notice from Nasdaq
9 Mar 23
8-K
Changes in Registrant's Certifying Accountant
1 Mar 23
10-Q
2023 Q3
Quarterly report
24 Feb 23
8-K
Submission of Matters to a Vote of Security Holders
23 Feb 23
8-K/A
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
22 Feb 23
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
21 Feb 23
NT 10-Q
Notice of late quarterly filing
14 Feb 23
Latest ownership filings
4
Salim Natha
1 Feb 22
4
Thomas Peter Moore
1 Feb 22
4
Justin James Mclarney
1 Feb 22
4
Timothy Christopher Johnson
1 Feb 22
4
Dewan Fazlul Hoque Chowdhury
1 Feb 22
4
Bashir Timol
1 Feb 22
3
Thomas Peter Moore
10 Nov 21
3
Timothy Christopher Johnson
2 Nov 21
3
Justin James Mclarney
2 Nov 21
4
Bashir Timol
7 Jun 18
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 7.34 mm | 7.34 mm | 7.34 mm | 7.34 mm | 7.34 mm | 7.34 mm |
| Cash burn (monthly) | 922.94 k | 1.31 mm | 211.11 k | 645.92 k | 513.70 k | 686.73 k |
| Cash used (since last report) | 2.77 mm | 3.93 mm | 633.36 k | 1.94 mm | 1.54 mm | 2.06 mm |
| Cash remaining | 4.57 mm | 3.41 mm | 6.71 mm | 5.40 mm | 5.80 mm | 5.28 mm |
| Runway (months of cash) | 5.0 | 2.6 | 31.8 | 8.4 | 11.3 | 7.7 |
Institutional ownership, Q3 2022
2.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 17 |
| Opened positions | 1 |
| Closed positions | 2 |
| Increased positions | 3 |
| Reduced positions | 5 |
| 13F shares | Current |
|---|---|
| Total value | 1.64 mm |
| Total shares | 787.02 k |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Tiger Management L.L.C. | 375.00 k | $780.00 k |
| Vanguard | 130.58 k | $272.00 k |
| Geode Capital Management | 108.18 k | $225.00 k |
| ARS Investment Partners | 81.16 k | $169.00 k |
| BLK Blackrock | 31.27 k | $65.00 k |
| Susquehanna International | 27.27 k | $57.00 k |
| NTRS Northern Trust | 17.95 k | $37.00 k |
| UBS UBS Group AG - Registered Shares | 5.73 k | $12.00 k |
| Tower Research Capital | 5.25 k | $11.00 k |
| WFC Wells Fargo & Co. | 3.12 k | $6.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Jan 22 | Justin James Mclarney | Common Stock | Grant | Acquire A | No | No | 0 | 22,293 | 0.00 | 22,293 |
| 28 Jan 22 | Dewan Fazlul Hoque Chowdhury | Stock Option Common Stock | Grant | Acquire A | No | No | 3.98 | 8,000 | 31.84 k | 8,000 |
| 28 Jan 22 | Bashir Timol | Stock Option Common Stock | Grant | Acquire A | No | No | 3.98 | 8,000 | 31.84 k | 8,000 |
| 28 Jan 22 | Timothy Christopher Johnson | Stock Option Common Stock | Grant | Acquire A | No | No | 3.98 | 8,000 | 31.84 k | 8,000 |
| 28 Jan 22 | Thomas Peter Moore | Stock Option Common Stock | Grant | Acquire A | No | No | 3.98 | 8,000 | 31.84 k | 8,000 |
News
EF Hutton Reiterates Buy on Nemaura Medical, Maintains $6 Price Target
30 Mar 23
Stocks That Hit 52-Week Lows On Monday
20 Mar 23
Stocks That Hit 52-Week Lows On Thursday
16 Mar 23
EF Hutton Maintains Buy on Nemaura Medical, Maintains $6 Price Target
28 Feb 23
HC Wainwright & Co. Maintains Buy on Nemaura Medical, Lowers Price Target to $7
27 Feb 23
Press releases
Nemaura Medical to Participate in Fireside Chat Hosted by EF Hutton
21 Mar 23
Nemaura Medical Announces Receipt of Notice from Nasdaq
9 Mar 23
Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update
24 Feb 23
Nemaura Medical to Participate in Fireside Chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Virtual Conference
16 Feb 23
Nemaura Medical Announces Closing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement
31 Jan 23